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ABSTRACT
Objectives To examine the association between coffee, 
including caffeinated and decaffeinated coffee, with 
hepatocellular carcinoma (HCC) and assess the influence 
of HCC aetiology and pre-existing liver disease.
Design We performed a systematic review and meta-
analysis. We calculated relative risks (RRs) of HCC 
according to caffeinated and decaffeinated coffee 
consumption using a random-effects dose–response 
meta-analysis. We tested for modification of the effect 
estimate by HCC aetiology and pre-existing liver disease. 
We judged the quality of evidence using the Grading 
of Recommendations Assessment, Development and 
Evaluation (GRADE) criteria.
Results We found 18 cohorts, involving 2 272 642 
participants and 2905 cases, and 8 case–control studies, 
involving 1825 cases and 4652 controls. An extra two cups 
per day of coffee was associated with a 35% reduction in 
the risk of HCC (RR 0.65, 95% CI 0.59 to 0.72). The inverse 
association was weaker for cohorts (RR 0.71, 95% CI 
0.65 to 0.77), which were generally of higher quality than 
case–control studies (RR 0.53, 95% CI 0.41 to 0.69). There 
was evidence that the association was not significantly 
altered by stage of liver disease or the presence/absence 
of high alcohol consumption, high body mass index, type 
2 diabetes mellitus, smoking, or hepatitis B and C viruses. 
An extra two cups of caffeinated and decaffeinated coffee 
(2 and 3 cohort studies, respectively) were associated with 
reductions of 27% (RR 0.73, 95% CI 0.63 to 0.85) and 14% 
(RR 0.86, 95% CI 0.74 to 1.00) in the risk of HCC. However, 
due to a lack of randomised controlled trials, potential 
publication bias and there being no accepted definition of 
coffee, the quality of evidence under the GRADE criteria 
was ‘very low’.
Conclusions Increased consumption of caffeinated coffee 
and, to a lesser extent, decaffeinated coffee are associated 
with reduced risk of HCC, including in pre-existing liver 
disease. These findings are important given the increasing 
incidence of HCC globally and its poor prognosis.
INTRODUCTION
Primary liver cancer is the sixth most commonly 
diagnosed cancer worldwide, and because of 
its poor prognosis the second leading cause 
of cancer death.1 2 Hepatocellular carcinoma 
(HCC) is the dominant histological subtype 
accounting for 85%–90% of cases.3 HCC most 
commonly develops in people with cirrhosis 
due to chronic viral hepatitis B (HBV) or 
hepatitis C (HCV), excess alcohol consump-
tion, and/or non-alcoholic fatty liver disease.3 
Non-alcoholic steatohepatitis (NASH), which 
is rapidly increasing worldwide, can lead to 
the development of HCC in the absence of 
cirrhosis.4 The incidence of liver cancer is 
increasing due to changes in these under-
lying risks, and by 2030 the number of new 
cases annually will have risen by around 
50% to over 1.2 million.5 The burden of liver 
cancer is highest in East and South-East Asia, 
with China alone accounting for 50% of cases 
worldwide.2 Only 10%–37% of patients diag-
nosed with HCC are eligible for potentially 
curative tumour resection (partial hepatec-
tomy).6 Thus, prognosis remains poor, with a 
5-year overall survival rate of 18%.7
Coffee is a popular drink in most coun-
tries, with approximately 2.25 billion cups 
consumed daily.8 It is a complex mixture 
of biologically active molecules, including 
caffeine, chlorogenic acid and diterpenes.9 
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Strengths and limitations of this study
 ► This is the first meta-analysis to calculate the relative 
risks  (RRs) of hepatocellular carcinoma  (HCC) for 
1–5 cups of coffee per day, which may be useful 
in the design of a coffee-based intervention for 
evaluation in a clinical trial.
 ► This is the first meta-analysis to investigate the 
influence of all the main HCC risk factors on the 
association between coffee and HCC.
 ► This is the first meta-analysis to calculate the RR of 
HCC for decaffeinated coffee consumption.
 ► There was heterogeneity between the studies 
included in the meta-analysis.
 ► Many studies did not specify coffee caffeine content.
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These compounds possess antioxidant, anti-inflam-
matory, antifibrotic and anticarcinogenic properties, 
which may explain the observational data that coffee 
drinkers have lower rates of chronic liver disease (CLD), 
including fibrosis, cirrhosis and HCC.10 Reports by the 
World Cancer Research Fund (WCRF)11 and the Inter-
national Agency for Research on Cancer (IARC)12 are 
both supportive of a protective role of coffee against 
HCC. In addition, a recent meta-analysis reported that 
the relative risk (RR) of HCC for an extra cup of coffee 
per day was 0.74 (95% CI 0.65 to 0.83).13 However, to 
date no randomised controlled trials (RCTs) investigating 
a coffee intervention for preventing HCC have been 
performed. Challenges in designing such a trial include 
a lack of understanding of the effect modification by aeti-
ology or risk factors for HCC (eg, alcohol liver disease, 
NASH, cirrhosis, etc). In addition, there is uncertainty 
as to whether all types of coffee are equally beneficial, 
especially given their differing chemical compositions 
(eg, caffeinated vs decaffeinated coffee). To help address 
these challenges, we have now explored, for the first time 
in a meta-analysis, the modification of the inverse associa-
tion between coffee and HCC by key risk factors, such as 
HBV/HCV, high body mass index (BMI), type 2 diabetes 
mellitus (T2DM), smoking, alcohol consumption and 
the presence of CLD including cirrhosis. We also report 
the first meta-analysis for the association between decaf-
feinated coffee and HCC. Decaffeinated coffee protects 
against liver damage in animal studies14 and is inversely 
associated with T2DM, abnormal liver function tests and 
cirrhosis in human observational studies.15–17
METHODS
The methods used were similar to those described in 
our earlier work18 and are detailed below. We followed 
the PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses) guidelines; a protocol, which 
was prespecified but not preregistered online, is provided 
as online supplementary file information.
Searches and selection of studies
We performed searches of abstracts and titles in Web of 
Science, Embase and PubMed with the following: (‘odds’ 
OR ‘risk’ OR ‘hazard’ OR ‘OR’ OR ‘RR’ OR ‘HR’) AND 
‘coffee’ AND (‘liver’ OR ‘hepatocellular*’) AND (‘cancer 
‘OR ‘carcino*’ OR ‘neoplas*’). The searches were run in 
September 2015 without restriction of date of publication. 
References of pertinent studies were searched manually. 
After removing duplicates, OK and RB independently 
screened the titles and abstracts of the studies found in the 
search. Studies that were included (1) reported an RCT, 
case–control study or cohort study; and (2) reported HRs, 
ORs or RRs with 95% CIs for HCC in adults according 
to consumption of coffee. Studies that were excluded (1) 
did not report a dose–response or give sufficient informa-
tion for calculation of a dose–response (ie, this requires 
estimates for more than two exposure levels, or (ii) 
were non-English-language studies. We assumed cases of 
primary liver cancer to be HCC. If studies overlapped, we 
included the largest study or otherwise the last published 
study. We worked from published studies only, including 
abstracts, although we unsuccessfully attempted to 
acquire unpublished data from the authors of one study, 
as indicated below.
Extraction of data and assessment of quality
We extracted the following information from each study: 
the first author, the date of publication, the geographic 
region, the design of the study, the exclusion and inclu-
sion criteria, the estimates and adjustments, the numbers 
of participants (or controls) and cases, the methods of 
measuring exposure, and case identification. We also 
extracted data concerning cohort follow-up (time, 
losses) and whether baseline liver disease was excluded. 
We extracted the most rigorously adjusted effect sizes. 
We extracted effect sizes stratified by pre-existing CLD, 
smoking status, alcohol consumption, BMI, HBV and 
HCV status, T2DM, and type of coffee. OK extracted the 
data, which RB then checked. Given the low incidence of 
HCC, we considered ORs, RRs and HRs to be equivalent, 
and for simplicity we used RR to refer to all three herein. 
We assessed the quality of the included studies using 
the Newcastle-Ottawa Scale.19 We judged the quality of 
evidence with the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE).20
Statistical methods
Coffee and HCC
Most studies did not distinguish caffeinated versus decaf-
feinated coffee, so coffee was taken to be the pattern 
of use prevalent in the particular study population. We 
considered consumption in cups, where necessary21 
converting millilitres into cups of 150 mL. For each study, 
we calculated an RR for an extra two cups per day using 
dose–response data where available22 23 or by estimating 
the dose–response using the method of Greenland and 
Longnecker.24 The unit of an ‘extra two cups’ per day 
was selected to represent a potential coffee-based inter-
vention, which could be used in clinical trials, and to 
maintain comparability with a previous meta-analysis.25 
We estimated the median consumption for each reported 
consumption category to be the midpoint of closed 
ranges and the midpoint added to the amplitude of the 
previous range for open ranges.25 We assessed whether the 
dose–response was non-linear by a cubic spline meta-anal-
ysis.26 We tested for statistical heterogeneity using I2 
and Cochran's Q,27 and interpreted p values of <0.1 as 
statistically significant (for heterogeneity only), and we 
interpreted the I2 values according to chapter 9.5.2 of the 
Cochrane handbook.27 We investigated heterogeneity by 
meta-regression and examined the impact of individual 
studies by rerunning the analysis while leaving the studies 
out one at a time.28 We tested for publication bias using 
Egger’s test and a ‘trim-and-fill’ analysis,29 which we used 
to adjust the estimate for missing studies if publication 
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bias was indicated. To assess the magnitude and direction 
of adjustment, we calculated a pooled unadjusted effect 
sizes for comparison with the corresponding adjusted 
effect size. We used random-effects models (DerSimo-
nian-Laird) and a two-sided p value >0.05 for statistical 
significance. We used R (R Foundation for Statistical 
Computing, Vienna, Austria) with the metafor30 and 
dosresmeta31 packages for the analyses.
Effect modification by risk factors
We calculated the RRs of HCC according to coffee 
consumption in participants stratified by baseline CLD. 
We also calculated and meta-analysed RRs stratified 
by exposure to each of viral hepatitis status (carriers of 
HBV/HCV vs negative for both), BMI (highest vs lowest 
BMI categories), T2DM (presence vs absence), alcohol 
consumption (highest vs lowest categories) and smoking 
(current smoker vs ex/non-smoker). For these analyses, 
we only included studies that provided RRs for both 
exposed and non-exposed to the risk factors. Where avail-
able,22 23 we used dose–response data to calculate RRs for 
an increase in two cups of coffee per day. Otherwise, we 
used the Greenland and Longnecker method,24 where the 
number of exposed and non-exposed was provided32–35 
and variance-weighted least squares regression where they 
were not.36–39 For each risk factor, we calculated a p value 
for its modifying effect on the association between coffee 
and HCC by meta-analysing the differences between the 
exposed and unexposed RRs from each study. We also 
calculated the τ2 for each of these analyses.
Caffeinated and decaffeinated coffee and HCC
Where possible we extracted data separately for caffein-
ated and decaffeinated coffee and calculated pooled RRs 
of HCC per two extra cups per day of each. One study, 
Bamia et al,21 reported RRs of HCC according to decaffein-
ated coffee consumption for three qualitative categories: 
‘non-consumers’, ‘consumers below the median’ and 
‘consumers at/above the median’. We were unable to get 
the corresponding quantitative values after contacting 
the authors, so we used those reported by another publi-
cation investigating the effect of decaffeinated coffee on 
oesophageal cancer in the same cohort.40 As above, we 
used dose–response data where available.22 Otherwise, we 
calculated the dose–response using the Greenland and 
Longnecker method,24 where the number of exposed 
and non-exposed15 was available and variance-weighted 
least squares regression where they were not.21
RESULTS
Coffee consumption and HCC
Figure 1 shows the searches and the stages of the selec-
tion of studies. Once duplicates were removed, we 
screened the abstracts and titles of 181 studies. Of those, 
we reviewed 34 studies in their entirety. Tables 1A and 
1B summarise the characteristics of the 16 studies that 
we included in the main meta-analysis.15 21–23 32 33 35–39 41–45 
The studies were published between 2002 and 2015. 
Seven were from Europe, five from Japan, two from the 
USA and one from each of Hong Kong and Singapore. 
The cohort studies primarily involved general popula-
tions (eg, randomly selected from population registries), 
except for Lai et al,23 which included male smokers only. 
Total follow-ups ranged from 739 to 24 years,23 and linkage 
to cancer registries was generally used to identify cases 
and exclude baseline HCC. The case–control studies 
were hospital-based, with only one33 using community 
controls. Fifteen studies reported estimates according to 
‘coffee’ consumption, while two and four studies, respec-
tively, reported estimates specifically for caffeinated and 
decaffeinated coffee. The quality scores ranged from 4 
to 8 (tables 1A and 1B) and were generally higher for 
cohorts (mean=6.9) compared with case–control studies 
(mean=5.0). A number of studies reported data from 
multiple cohorts or case–control studies. We extracted 
pooled estimates from Petrick et al22 (nine cohorts) and 
Gallus et al37 (two case–control studies) as equivalent 
study-specific estimates (eg, in terms of adjustments for 
confounders and categories of coffee consumption) were 
not available. We extracted separate RRs from Shimazu et 
al39 (two cohorts). Thus, this meta-analysis included data 
from 18 cohorts, involving 2 272 642 participants and 
2905 cases, and 8 case–control studies, involving 1825 
cases and 4652 controls.
The RRs of HCC according to coffee consumption 
are summarised in table 2, including adjustments for 
confounders. Most studies adjusted for age, alcohol and 
smoking, and a smaller number for HBV/HCV, BMI 
and T2DM. All the studies showed an inverse association 
between HCC for an extra two cups of coffee per day, 
although in four studies the relationship was not statis-
tically significant. The pooled RR of HCC for an extra 
two cups per day across all studies for coffee was 0.65 
(95% CI 0.59 to 0.72) (figure 2), for cohort studies it was 
0.71 (95% CI 0.65 to 0.77) and for case–control studies 
0.53 (95% CI 0.41 to 0.69). The pooled RR from studies 
with a quality score of 6 or above was 0.70 (95% CI 0.64 
to 0.76) compared with 0.50 (95% CI 0.35 to 0.70) for 
those scoring below 6. The p value for non-linearity of 
the dose–response was not statistically significant, and the 
pooled RRs for different levels of consumption of up to 
five cups per day are illustrated in figure 3. Adjustment 
for confounders had minimal effect, changing the pooled 
RR from 0.62 (95% CI 0.53 to 0.72) (ie, unadjusted) to 
0.65 (95% CI 0.59 to 0.72).
Heterogeneity and sensitivity analysis
The I2 and the p value for Cochran’s Q were 58.5% 
and <0.01, respectively (figure 2), which indicated 
‘moderate’ to ‘substantial’ between-study heterogeneity. 
Heterogeneity was lower for cohorts (I2=40.7%; p=0.09) 
than case–control studies (I2=64.3%; p<0.01). In the sensi-
tivity analysis, the RR was strongest when we excluded 
Hu et al38 (RR 0.63, 95% CI 0.56 to 0.71) and weakest 
when we excluded Tanaka et al33 (RR 0.68, 95% CI 0.62 
to 0.74). Heterogeneity remained statistically significant 
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throughout. In the meta-regression analysis, we found no 
statistically significant association of RR and publication 
year, length of follow-up (cohorts only), percentage of 
alcohol abstainers, age or gender.
Publication bias and quality of evidence
We found evidence of publication bias by Egger's test 
(p<0.0001) and visual inspection of the funnel plot as 
shown in figure 4. In our trim-and-fill analysis, we detected 
a number of ‘missing’ smaller studies. Calibration for 
missing studies pushed the effect size of coffee towards 
null from 0.65 (95% CI 0.59 to 0.72) to 0.71 (95% CI 0.64 
to 0.79). The evidence quality that coffee protects against 
HCC as determined with GRADE was ‘very low’ (table 3).
The effect of pre-existing CLD and HCC risk factors
Three cohort studies35 36 39 performed subgroup analyses 
stratified by presence/absence of baseline CLD, which 
was poorly defined but included cirrhosis. Data from two 
of those studies showed an inverse association of coffee 
and HCC in those with baseline CLD but not without, 
while the other showed an inverse association without 
baseline CLD only. The pooled difference between the 
stratified estimates was not statistically significant (p=0.87). 
Figure 1 An illustration showing how the studies included in this meta-analysis were reviewed and selected. HCC, 
hepatocellular carcinoma; HCV, hepatitis C virus.
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Data from a fourth (case–control) study33 showed statisti-
cally significant inverse associations between coffee and 
HCC, both when cases were compared with commu-
nity controls and controls with CLD, 22% of whom had 
cirrhosis. Three other case–control studies37 43 45 showed 
inverse associations between coffee and HCC using only 
controls with liver disease.
Results from the investigation into the influence of risk 
factors on the association between coffee and HCC are 
presented as online supplementary file information. In 
summary, there was no statistically significant difference 
in the associations between coffee and HCC according 
to viral hepatitis status, smoking, BMI, T2DM or alcohol 
consumption.
Caffeinated and decaffeinated coffee
Four studies reported RRs of HCC specifically for decaf-
feinated coffee consumption.15 21 22 32 No single study 
reported a statistically significant association between 
HCC and decaffeinated coffee consumption. Three 
cohort studies,15 21 22 involving approximately 750 000 
participants and 800 cases, reported dose–response RRs 
or RRs for >2 consumption categories. The pooled RR of 
HCC for two extra cups per day was 0.86 (95% CI 0.74 to 
1.00; three studies). Only two studies, involving approxi-
mately 850 000 participants and 900 cases, reported RRs 
of HCC according to caffeinated coffee consumption in 
a manner suitable for dose–response analysis.15 22 The 
pooled RR of HCC for an extra two cups of caffeinated 
coffee was 0.73 (95% CI 0.63 to 0.85).
DISCUSSION
In our meta-analysis of 18 cohort studies, involving 
2 272 642 participants and 2905 cases, and 8 case–control 
studies, involving 1825 cases and 4652 controls, increasing 
coffee consumption by two cups per day was associated 
with a 35% reduction in the risk of HCC (RR 0.65; 95% CI 
0.59 to 0.72). This is similar to previous meta-analyses.13 25 
In a subset of studies, the association was not significantly 
different in participants with pre-existing CLD at base-
line, some of whom had cirrhosis. This is an important 
finding as the absolute risk of HCC in cirrhosis is high 
but may be more than halved by five cups per day of 
coffee compared with none (figure 3). The association 
was also not significantly different for the main exposures 
Figure 2 A forest plot illustrating RRs of HCC for an extra two cups of coffee per day. The RRs as reported by the individual 
studies are shown as squares. The sizes of the squares represent the weightings in the random-effects model. The pooled 
RRs (from cohorts, case–control studies and all studies) are shown as diamonds. HCC, hepatocellular carcinoma; RR, relative 
risks.
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Figure 3 Results of a cubic spline dose–response meta-analysis of the association between coffee and hepatocellular 
carcinoma.
Figure 4 Filled funnel plot for the risk of HCC per extra two cups of coffee daily. Black circles represent the included 
studies found by our search, while white circles represent the ‘missing’ unpublished studies detected in the trim-and-fill 
analysis. HCC, hepatocellular carcinoma; RR, relative risk.
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for HCC: high alcohol consumption, smoking, high BMI, 
T2DM and HBV/HCV.46 Data from the few studies that 
specified coffee type showed that increasing caffeinated 
and decaffeinated coffee consumption by two cups per 
day was associated with reductions of 27% (RR 0.73, 
95% CI 0.63 to 0.85) and 14% (RR 0.86, 95% CI 0.74 to 
1.00) in the risk of HCC. This is the strongest evidence 
to date of an association between decaffeinated coffee 
and HCC. It may be important for developing coffee as 
a lifestyle intervention in CLD, as decaffeinated coffee 
might be more acceptable to those who do not drink 
coffee or who limit their coffee consumption because 
of caffeine-related symptoms. However, the benefits of 
decaffeinated coffee appear to be smaller and less certain 
than for caffeinated coffee.
Other major strengths of this meta-analysis are the 
systematic approach used to calculate a dose–response 
between coffee and HCC and the inclusion of a large 
number of participants and cases, representing a range of 
demographic groups (eg, gender, nationality, etc) and the 
main risk factors for HCC. We did not detect effect modi-
fication by baseline CLD and HCC aetiology, although 
our analysis was limited by the small number of studies 
that provided the necessary data for these analyses.
The main limitation is that all the included studies were 
observational, and thus we cannot infer causation. Obser-
vational studies are susceptible to bias and confounding, 
and case–control studies are at particular risk of selection 
and information bias. In the case–control studies, cases 
were mostly from hospital admissions or clinic records, 
which may not be representative of all HCC. Not all 
patients with HCC are admitted to hospitals, and indi-
vidual factors associated with likelihood to attend clinic 
and/or to participate in a research study may be associ-
ated with coffee consumption or other risk factors (and 
confounders) for HCC. In addition, because of the need 
to interview participants, dead cases were not included.
The use of hospital controls in all except one study may 
also have introduced bias. First, there are associations 
between coffee drinking and a large number of other 
health conditions.47 Second, hospitals vary in the scale of 
their catchment areas and so hospital controls may not be 
representative of the populations from which cases arose, 
especially in areas where HCC care is highly specialised.
Among the cohorts, some studies used primary liver 
cancer as an outcome, whereas others used HCC. All but 
one cohort study used cancer registries to identify cases, 
sometimes in combination with death records. Cancer 
registries are more robust for ascertainment than death 
records.
Residual confounding likely existed in all studies 
from hidden factors and misclassification of measured 
confounders. However, adjustment for confounders had 
minimal effect on the association between coffee and 
HCC, suggesting residual effects will be small. All studies 
adjusted for alcohol, but several did not adjust for BMI, 
T2DM and HBV/HCV. Coffee was associated with alcohol 
in some studies, so failure to capture alcohol robustly T
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might underestimate the inverse association between 
coffee and HCC.15 41 The cohorts generally did not adjust 
for HBV/HCV despite it being a major risk factor for 
HCC, but prevalence was likely low and we found no 
evidence of an effect of HBV/HCV infection on the asso-
ciation between coffee and HCC.
The measurement of coffee consumption may also 
have introduced bias in case–control studies due to recall 
bias. Belief that coffee was harmful may have led to over-
estimation of consumption in cases. However, cases may 
have reduced coffee consumption because liver disease 
slows caffeine metabolism.48 One study used for baseline 
the consumption at 2 years before HCC diagnosis,32 when 
decades before may have been more appropriate. Another 
study43 reported RRs of HCC according to consumption 
preidentification and postidentification of liver disease; 
the weaker preidentification estimates were used in the 
meta-analysis, with minimal effect on the overall pooled 
RR.
In the cohorts, baseline CLD may have been present 
in cases given the short follow-up time of some cohorts 
compared with the long time for HCC to develop. However, 
we looked at a number of cohorts that presented data 
stratified by baseline CLD status and found no significant 
effect on the association between coffee and HCC. Seti-
awan et al found that the RR of HCC for two or more cups 
of coffee daily compared with none remained comparable 
in magnitude and statistically significant when deaths in 
the first 2 years were excluded. Lai et al found that the RR 
of HCC for an extra cup of coffee per day was 0.81 (95% 
CI 0.66 to 0.98) in the first 10 years and 0.83 (95% CI 0.71 
to 0.96) in the final 10 years of the study. Bamia et al,21 
Hu et al38 and Shimazu et al39 reported similar findings. 
Thus, drinking coffee appeared to protect against HCC 
in participants with varying levels of undiagnosed CLD at 
baseline.
Our method of estimating median consumption in 
the reported consumption categories may have exagger-
ated the effect size. There was also a lack of data in most 
individual studies for higher levels of coffee consump-
tion (eg, five cups per day or above). As a result, we had 
limited ability to detect an upper threshold beyond which 
increasing consumption no longer provides any benefit 
with regard to the risk of HCC. This is evident from 
figure 3, which shows rapidly widening CIs above four 
cups of coffee per day.
There was statistically significant heterogeneity between 
the studies; in a meta-regression analysis, it was not signifi-
cantly associated with publication year, length of follow-up 
(cohorts only), percentage of alcohol abstainers, age or 
gender of participants.
Heterogeneity might be due to how consumption of 
coffee was measured. The included studies asked partici-
pants to estimate coffee consumption, usually by selecting 
from a list of predefined categories in food frequency 
questionnaires. Different categories may have influenced 
participants’ responses. There may be variation in the size 
of cups, preparation (eg, boiled vs filtered) and caffeine 
content; ‘coffee’ was taken to be the pattern of use prev-
alent in the particular study population. Proportions of 
decaffeinated coffee drinkers varied markedly and were 
very low in certain countries (eg, Japan and Finland).33 38 
Higher proportions of decaffeinated coffee drinkers, such 
as in the USA,22 may have attenuated the overall effect 
size given the weaker association found here between 
decaffeinated coffee and HCC.
Language bias cannot be excluded as we only included 
English studies, although studies found in the search 
were mostly in English. Generally, evidence of a signifi-
cant influence in meta-analyses of language bias is weak.49 
Studies published in non-English journals may also be 
less rigorous and report bigger effect estimates.50 Thus, 
our inclusion of English studies only is not likely to have 
introduced significant bias. Finally, we found evidence of 
publication bias using Egger’s test. Adjusting for smaller 
unpublished studies pushed the effect size towards null, 
but it remained statistically significant.
Our study adds to the weight of evidence considered 
by the IARC and WCRF that coffee is protective against 
HCC. However, when assessed under the GRADE criteria, 
the quality of evidence supporting coffee for the preven-
tion of HCC was still ‘very low’. This was mainly because 
of the lack of randomised trials, evidence of publication 
bias, and the fact that ‘coffee’, which has various formu-
lations with different chemical properties, is not well 
defined.
Mechanism of action
As discussed in detail in previous work,18 51 there is biolog-
ical plausibility of a protective effect of coffee against HCC. 
The fact that we found no significant effect of aetiology 
albeit in a subset of studies suggests that the apparent 
protective mechanism acts via a common pathway, such 
as the development of cirrhosis. Eighty to ninety per cent 
of cases of HCC develop on a background of cirrhosis,51 
and several studies and a meta-analysis have reported an 
inverse association between coffee and cirrhosis.18 Coffee 
may possess direct anticarcinogenic properties, which is 
supported by our finding that the association of coffee and 
HCC was seen in those with pre-existing CLD, including 
cirrhosis. Our findings suggest a central role for caffeine, 
given that the association was weaker for decaffeinated 
coffee. Caffeine reduces HCC cell proliferation.52 Cafestol 
and kahweol increase activity of phase 2 liver enzymes, 
which may improve metabolism and excretion of carcin-
ogens,53 54 and compounds including polyphenols may 
ameliorate oxidative DNA damage. However, cafestol and 
kahweol are present only in minimal quantities in instant 
and filtered coffee,55 and these varieties are popular in 
Japan and Finland, respectively, where studies included in 
this meta-analysis show inverse associations with HCC.33 38 
Other specific mechanisms of protection might include 
inhibition of hepatitis virus activity56 and prevention of 
T2DM.38
Coffee purportedly possesses a range of health effects in 
addition to those on the liver, including lower incidences 
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of neurological diseases, various cancers and any-cause 
mortality.47 However, randomised trials are needed of inter-
ventions to support patients at risk of HCC to increase coffee 
consumption before recommending an increase given the 
examples in other areas of where RCTs have shown observa-
tional data to be incorrect and the global scale and ubiquity 
of coffee consumption.57 The potential harms of coffee 
also require further investigation, including the reported 
increased risk of lung cancer and bone fractures47 and the 
deleterious effect on cholesterol, which could potentially 
exacerbate the already increased risk of CVD associated 
with certain types of liver disease.58
In summary, this study has shown that an extra two cups 
of coffee per day is associated with a one-third reduction 
in the RR of HCC. Our findings are significant given the 
increasing incidence of HCC and the overall poor prognosis 
of this condition. Randomised trials should investigate the 
effectiveness of increasing coffee consumption in those at 
risk of HCC including patients with existing CLD.
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